Karen S. Lynch
Karen S. Lynch's purchase track record
Karen S. Lynch has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/3/2023 | CVS | $977K | +9.9% | -0.3% | +3.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ADP Featured in Dividend and Peer Comparison Reports. Recent coverage highlights ADP as a stable dividend option and compares its performance against professional services peers. Analysts from TD Cowen included the company in a list of human capital management stocks to watch. The stock is currently trading near its 52-week high, with an average analyst target of $286.40.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
Transaction History
| TMO | ▲ Buy | Grant | 499 | $0 | 5/20/2026 | View on chart |
| ADP | ▲ Buy | Grant | 1,453 | $0 | 11/12/2025 | View on chart |
| TMO | ▲ Buy | Grant | 565 | $0 | 5/21/2025 | View on chart |
| TMO | ▲ Buy | Grant | 95 | $0 | 2/19/2025 | View on chart |
| CVS | ▲ Buy | Grant | 45,248 | $3.6M | 4/1/2024 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 61,953 | $4.9M | 4/1/2024 | View on chart |
| CVS | ▲ Buy | Grant | 136,640 | $0 | 2/12/2024 | View on chart |
| CVS | ▲ Buy | Open Market | 14,000 | $977K | 5/3/2023 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 93,677 | $7.0M | 4/1/2023 | View on chart |
| CVS | ▲ Buy | Grant | 206,610 | $0 | 2/2/2023 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 116,940 | $11.8M | 4/1/2022 | View on chart |
| CVS | ▲ Buy | Grant | 257,916 | $0 | 2/21/2022 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 14,121 | $1.3M | 11/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery
Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.